- Home
- ALT vs EDD Comparison
ALT vs EDD Comparison
Compare ALT & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- EDD
- Stock Information
- Founded
- ALT 1997
- EDD 2007
- Country
- ALT United States
- EDD United States
- Employees
- ALT N/A
- EDD N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- EDD Finance Companies
- Sector
- ALT Health Care
- EDD Finance
- Exchange
- ALT Nasdaq
- EDD Nasdaq
- Market Cap
- ALT 292.0M
- EDD 329.4M
- IPO Year
- ALT N/A
- EDD N/A
- Fundamental
- Price
- ALT $3.83
- EDD $5.30
- Analyst Decision
- ALT Strong Buy
- EDD
- Analyst Count
- ALT 6
- EDD 0
- Target Price
- ALT $17.40
- EDD N/A
- AVG Volume (30 Days)
- ALT 3.0M
- EDD 254.3K
- Earning Date
- ALT 08-12-2025
- EDD 01-01-0001
- Dividend Yield
- ALT N/A
- EDD 7.52%
- EPS Growth
- ALT N/A
- EDD N/A
- EPS
- ALT N/A
- EDD N/A
- Revenue
- ALT $20,000.00
- EDD N/A
- Revenue This Year
- ALT N/A
- EDD N/A
- Revenue Next Year
- ALT $761,880.20
- EDD N/A
- P/E Ratio
- ALT N/A
- EDD N/A
- Revenue Growth
- ALT N/A
- EDD N/A
- 52 Week Low
- ALT $2.90
- EDD $4.22
- 52 Week High
- ALT $11.16
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- ALT 51.79
- EDD 56.10
- Support Level
- ALT $3.35
- EDD $5.24
- Resistance Level
- ALT $3.66
- EDD $5.42
- Average True Range (ATR)
- ALT 0.19
- EDD 0.05
- MACD
- ALT 0.07
- EDD -0.01
- Stochastic Oscillator
- ALT 86.18
- EDD 40.00
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.